'Are you guys out of virology?': Not hardly, says Gilead execs, as they buy a late-stage drug company for $1.7B
The CEO has struck a deal to buy out Germany’s MYR GmbH, a privately held biotech which has an advanced drug for hepatitis delta virus that fits well with their focus on hepatitis B, for $1.7 billion. Most of that is in cash, with $360 million on the table for an FDA approval.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.